



Clinical trial results:

A Randomized, Double-blind Phase 3 Study to Assess the Efficacy and Safety of ABP 710 Compared to Infliximab in Subjects With Moderate to Severe Rheumatoid Arthritis

Summary

| | |
|--------------------------|-------------------|
| EudraCT number | 2014-004704-29 |
| Trial protocol | CZ ES HU DE BG PL |
| Global end of trial date | 13 August 2018 |

Results information

| | |
|--------------------------------|----------------|
| Result version number | v1 (current) |
| This version publication date | 24 August 2019 |
| First version publication date | 24 August 2019 |

Trial information

Trial identification

| | |
|-----------------------|----------|
| Sponsor protocol code | 20140111 |
|-----------------------|----------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT02937701 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | Amgen Inc. |
| Sponsor organisation address | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320 |
| Public contact | IHQ Medical Info-Clinical Trials, Amgen (EUROPE) GmbH, MedInfoInternational@amgen.com |
| Scientific contact | IHQ Medical Info-Clinical Trials, Amgen (EUROPE) GmbH, MedInfoInternational@amgen.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|----------------|
| Analysis stage | Final |
| Date of interim/final analysis | 13 August 2018 |
| Is this the analysis of the primary completion data? | No |
| Global end of trial reached? | Yes |
| Global end of trial date | 13 August 2018 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

The primary objective was to assess the efficacy of ABP 710 compared with US-licensed infliximab.

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonisation (ICH) regulations and guidelines regarding Good Clinical Practice (GCP), clinical safety data management, and scientific integrity; with United States (US) Food and Drug Administration (FDA) regulations set forth in 21 Code of Federal Regulations Parts 50, 56, and 312; and with European Union (EU) Community Directives 2001/20, 2001/83, 2003/94, and 2005/28 as enacted into local law.

Prior to initiation at each study center, the study protocol was reviewed by an Institutional Review Board (IRB) or Institutional Ethics Committee (IEC).

All subjects were to provide written informed consent prior to entering the study and before initiation of any study-related procedure (including administration of investigational product). The investigator was responsible for explaining the benefits and risks of participation in the study to each subject or the subject's legally acceptable representative and for obtaining written informed consent.

Background therapy: -

Evidence for comparator: -

| | |
|---|-----------------|
| Actual start date of recruitment | 10 October 2016 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|---------------------|
| Country: Number of subjects enrolled | Poland: 258 |
| Country: Number of subjects enrolled | Czech Republic: 101 |
| Country: Number of subjects enrolled | Germany: 26 |
| Country: Number of subjects enrolled | Bulgaria: 25 |
| Country: Number of subjects enrolled | Hungary: 21 |
| Country: Number of subjects enrolled | Spain: 11 |
| Country: Number of subjects enrolled | United States: 104 |
| Country: Number of subjects enrolled | Canada: 3 |
| Country: Number of subjects enrolled | Australia: 9 |
| Worldwide total number of subjects | 558 |
| EEA total number of subjects | 442 |

Notes:

| Subjects enrolled per age group | |
|---|-----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 434 |
| From 65 to 84 years | 124 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

This study was conducted at 75 centers in Australia, Bulgaria, Canada, Czech Republic, Germany, Hungary, Poland, Spain, and the United States.

Pre-assignment

Screening details:

Participants were randomized in a 1:1 ratio to receive ABP 710 or infliximab, stratified by geographic region and prior biologic use.

At week 22 participants initially randomized to infliximab were re-randomized in a 1:1 ratio to continue infliximab or switch to ABP 710. Participants initially randomized to ABP 710 continued receiving ABP 710.

Period 1

| | |
|------------------------------|---------------------------------|
| Period 1 title | Day 1 to Week 22 |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Assessor |

Arms

| | |
|------------------------------|---------|
| Are arms mutually exclusive? | Yes |
| Arm title | ABP 710 |

Arm description:

Participants randomized to receive a 3 mg/kg intravenous (IV) infusion of ABP 710 on day 1, at weeks 2 and 6, and every 8 weeks thereafter until week 22.

| | |
|--|----------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | ABP 710 |
| Investigational medicinal product code | ABP 710 |
| Other name | |
| Pharmaceutical forms | Powder for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

3-mg/kg IV infusion on day 1 (week 0), at weeks 2 and 6, and every 8 weeks thereafter.

| | |
|------------------|------------|
| Arm title | Infliximab |
|------------------|------------|

Arm description:

Participants randomized to receive 3 mg/kg IV infusion of infliximab on day 1, at weeks 2 and 6, and every 8 weeks thereafter until week 22.

| | |
|--|----------------------------------|
| Arm type | Active comparator |
| Investigational medicinal product name | Infliximab |
| Investigational medicinal product code | |
| Other name | Remicade® |
| Pharmaceutical forms | Powder for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

3-mg/kg IV infusion on day 1 (week 0), at weeks 2 and 6, and every 8 weeks thereafter.

| Number of subjects in period 1 | ABP 710 | Infliximab |
|--------------------------------------|---------|------------|
| Started | 279 | 279 |
| Received Treatment | 278 | 278 |
| Completed | 244 | 240 |
| Not completed | 35 | 39 |
| Adverse event, serious fatal | 1 | 1 |
| Consent withdrawn by subject | 6 | 6 |
| Physician decision | 2 | - |
| Dissatisfied with Treatment Efficacy | 5 | 9 |
| Adverse event, non-fatal | 11 | 14 |
| Other | 1 | - |
| Protocol Specified Criteria | 7 | 7 |
| Lost to follow-up | 1 | 1 |
| Protocol deviation | 1 | 1 |

Period 2

| | |
|------------------------------|---------------------------------|
| Period 2 title | Week 22 to Week 50 |
| Is this the baseline period? | No |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Assessor |

Arms

| | |
|------------------------------|-------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | ABP 710 / ABP 710 |

Arm description:

At week 22 participants initially randomized to ABP 710 continued receiving 3 mg/kg ABP 710 every 8 weeks through week 46.

| | |
|--|----------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | ABP 710 |
| Investigational medicinal product code | ABP 710 |
| Other name | |
| Pharmaceutical forms | Powder for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

3-mg/kg IV infusion administered every 8 weeks

| | |
|------------------|-------------------------|
| Arm title | Infliximab / Infliximab |
|------------------|-------------------------|

Arm description:

At week 22 participants initially randomized to infliximab were re-randomized to continue receiving 3 mg/kg infliximab every 8 weeks through week 46.

| | |
|----------|-------------------|
| Arm type | Active comparator |
|----------|-------------------|

| | |
|--|----------------------------------|
| Investigational medicinal product name | Infliximab |
| Investigational medicinal product code | |
| Other name | Remicade® |
| Pharmaceutical forms | Powder for solution for infusion |
| Routes of administration | Intravenous use |
| Dosage and administration details: | |
| 3-mg/kg IV infusion administered every 8 weeks | |
| Arm title | Infliximab / ABP 710 |

Arm description:

At week 22 participants initially randomized to infliximab were re-randomized to receive 3 mg/kg ABP 710 every 8 weeks through week 46.

| | |
|--|----------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | ABP 710 |
| Investigational medicinal product code | ABP 710 |
| Other name | |
| Pharmaceutical forms | Powder for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

3-mg/kg IV infusion administered every 8 weeks

| Number of subjects in period 2 | ABP 710 / ABP 710 | Infliximab / Infliximab | Infliximab / ABP 710 |
|---------------------------------------|-------------------|----------------------------|----------------------|
| Started | 244 | 121 | 119 |
| Completed | 212 | 113 | 110 |
| Not completed | 32 | 8 | 9 |
| Consent withdrawn by subject | 8 | 2 | 1 |
| Physician decision | 2 | - | 1 |
| Dissatisfied with Treatment Efficacy | 10 | 3 | 2 |
| Adverse event, non-fatal | 10 | 3 | 3 |
| Other | - | - | 1 |
| Lost to follow-up | 2 | - | 1 |

Baseline characteristics

Reporting groups

| | |
|---|------------|
| Reporting group title | ABP 710 |
| Reporting group description: | |
| Participants randomized to receive a 3 mg/kg intravenous (IV) infusion of ABP 710 on day 1, at weeks 2 and 6, and every 8 weeks thereafter until week 22. | |
| Reporting group title | Infliximab |
| Reporting group description: | |
| Participants randomized to receive 3 mg/kg IV infusion of infliximab on day 1, at weeks 2 and 6, and every 8 weeks thereafter until week 22. | |

| Reporting group values | ABP 710 | Infliximab | Total |
|---|---------|------------|-------|
| Number of subjects | 279 | 279 | 558 |
| Age, Customized | | | |
| Units: Subjects | | | |
| < 65 years | 217 | 217 | 434 |
| ≥ 65 years | 62 | 62 | 124 |
| Age Continuous | | | |
| Units: years | | | |
| arithmetic mean | 55.0 | 54.8 | |
| standard deviation | ± 11.72 | ± 11.42 | - |
| Sex: Female, Male | | | |
| Units: Subjects | | | |
| Female | 214 | 223 | 437 |
| Male | 65 | 56 | 121 |
| Race/Ethnicity, Customized | | | |
| Units: Subjects | | | |
| White | 265 | 267 | 532 |
| Black or African American | 12 | 12 | 24 |
| Asian | 2 | 0 | 2 |
| Ethnicity (NIH/OMB) | | | |
| Units: Subjects | | | |
| Hispanic or Latino | 18 | 13 | 31 |
| Not Hispanic or Latino | 261 | 266 | 527 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Geographic Region | | | |
| Units: Subjects | | | |
| Asia Pacific | 5 | 4 | 9 |
| Europe | 220 | 222 | 442 |
| North America | 54 | 53 | 107 |
| Prior Biologic Use for Rheumatoid Arthritis | | | |
| Units: Subjects | | | |
| Yes | 77 | 81 | 158 |
| No | 202 | 198 | 400 |
| Duration of Rheumatoid Arthritis (RA) | | | |
| Units: years | | | |
| arithmetic mean | 8.72 | 8.34 | |
| standard deviation | ± 7.914 | ± 7.604 | - |

| | | | |
|--|-----------|-----------|---|
| Swollen joint Count | | | |
| A total of 66 joints were scored for presence or absence of swelling. | | | |
| Units: joints | | | |
| arithmetic mean | 14.595 | 14.730 | |
| standard deviation | ± 8.0507 | ± 8.8315 | - |
| Tender Joint Count | | | |
| A total of 68 joints were scored for presence or absence of tenderness. | | | |
| Units: joints | | | |
| arithmetic mean | 23.109 | 23.764 | |
| standard deviation | ± 12.1648 | ± 13.3800 | - |
| Patient Global Health Assessment | | | |
| The participant's overall assessment of their disease activity in the past week assessed on a 100 mm visual analog scale (VAS), where 0 mm = No RA activity at all and 100 mm = Worst RA activity imaginable. | | | |
| Units: mm | | | |
| arithmetic mean | 65.4 | 64.1 | |
| standard deviation | ± 18.13 | ± 20.03 | - |
| Investigator's Global Health Assessment | | | |
| The investigator's assessment of the participant's current disease activity assessed on a 100 mm VAS where 0 mm = no activity at all (symptom-free and no arthritis symptoms) and 100 mm = worst activity imaginable (maximum arthritis disease activity). | | | |
| Units: mm | | | |
| arithmetic mean | 64.5 | 64.1 | |
| standard deviation | ± 15.88 | ± 15.76 | - |
| Patient's Assessment of Disease-related Pain | | | |
| The participant's assessment of their current level of pain assessed on a 100 mm horizontal VAS, where 0 mm = no pain at all and 100 mm = worst pain imaginable. | | | |
| Units: mm | | | |
| arithmetic mean | 63.5 | 61.5 | |
| standard deviation | ± 20.30 | ± 21.65 | - |
| Disability Index of the Health Assessment Questionnaire (HAQ-DI) | | | |
| The HAQ-DI is a patient-reported questionnaire consisting of 20 questions in eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. | | | |
| Units: units on a scale | | | |
| arithmetic mean | 1.44 | 1.42 | |
| standard deviation | ± 0.584 | ± 0.617 | - |
| C-reactive Protein (CRP) Concentration | | | |
| C-reactive protein (CRP) is a protein found in blood. CRP levels rise in response to inflammation. | | | |
| Units: mg/L | | | |
| arithmetic mean | 14.26 | 14.64 | |
| standard deviation | ± 20.171 | ± 23.117 | - |

End points

End points reporting groups

| | |
|---|-------------------------|
| Reporting group title | ABP 710 |
| Reporting group description: Participants randomized to receive a 3 mg/kg intravenous (IV) infusion of ABP 710 on day 1, at weeks 2 and 6, and every 8 weeks thereafter until week 22. | |
| Reporting group title | Infliximab |
| Reporting group description: Participants randomized to receive 3 mg/kg IV infusion of infliximab on day 1, at weeks 2 and 6, and every 8 weeks thereafter until week 22. | |
| Reporting group title | ABP 710 / ABP 710 |
| Reporting group description: At week 22 participants initially randomized to ABP 710 continued receiving 3 mg/kg ABP 710 every 8 weeks through week 46. | |
| Reporting group title | Infliximab / Infliximab |
| Reporting group description: At week 22 participants initially randomized to infliximab were re-randomized to continue receiving 3 mg/kg infliximab every 8 weeks through week 46. | |
| Reporting group title | Infliximab / ABP 710 |
| Reporting group description: At week 22 participants initially randomized to infliximab were re-randomized to receive 3 mg/kg ABP 710 every 8 weeks through week 46. | |

Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 22

| | |
|---|---|
| End point title | Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 22 |
| End point description: The primary efficacy endpoint was the response difference (RD) of 20% improvement in ACR core set measurements (ACR20) at week 22. A positive ACR20 response is defined if the following 3 criteria for improvement from baseline were met: <ul style="list-style-type: none">• ≥ 20% improvement in 68 tender joint count;• ≥ 20% improvement in 66 swollen joint count; and• ≥ 20% improvement in at least 3 of the 5 following parameters:<ul style="list-style-type: none">◦ Patient's assessment of disease-related pain (measured on a 100 mm visual analog scale [VAS]);◦ Patient's global health assessment (measured on a 100 mm VAS);◦ Investigator's global health assessment (measured on a 100 mm VAS);◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);◦ C-reactive protein concentration. The analysis was conducted in the intent-to-treat population which consisted of all randomized participants. Participants with missing data were counted as non-responders (non-responder imputation). | |
| End point type | Primary |
| End point timeframe: Baseline and week 22 | |

| End point values | ABP 710 | Infliximab | | |
|-----------------------------------|-----------------------|-----------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 279 | 279 | | |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | 68.1 (62.63 to 73.57) | 59.1 (53.37 to 64.91) | | |

Statistical analyses

| Statistical analysis title | Primary Analysis of ACR20 at Week 22 |
|----------------------------|--------------------------------------|
|----------------------------|--------------------------------------|

Statistical analysis description:

For the primary analysis of ACR20, the response difference (RD) was estimated by the Mantel-Haenszel (MH) estimate and the 90% confidence intervals (CIs) of RD were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use for RA).

| | |
|---|----------------------------|
| Comparison groups | ABP 710 v Infliximab |
| Number of subjects included in analysis | 558 |
| Analysis specification | Pre-specified |
| Analysis type | equivalence ^[1] |
| Parameter estimate | Response Difference |
| Point estimate | 9.37 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 2.67 |
| upper limit | 15.96 |

Notes:

[1] - Clinical equivalence for the primary endpoint was to be evaluated sequentially by first comparing the 2-sided 90% CI for RD of ACR20 at week 22 between ABP 710 and infliximab with an equivalence margin of (-15%, 15%). If the first test was successful, RD of ACR20 at week 22 was to be further evaluated by comparing the 2-sided 90% CI between ABP 710 and infliximab with an equivalence margin of (-12%, 15%).

| Statistical analysis title | Sensitivity Analysis of ACR20 at Week 22 |
|----------------------------|--|
|----------------------------|--|

Statistical analysis description:

A sensitivity analysis with the RD estimate and CIs for RD of ACR20 estimated using a generalized linear model with geographic region and prior biologic use for RA as covariates was also conducted.

| | |
|---|----------------------------|
| Comparison groups | ABP 710 v Infliximab |
| Number of subjects included in analysis | 558 |
| Analysis specification | Pre-specified |
| Analysis type | equivalence ^[2] |
| Parameter estimate | Response Difference |
| Point estimate | 9.3 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 2.67 |
| upper limit | 15.92 |

Notes:

[2] - Clinical equivalence for the primary endpoint was to be evaluated sequentially by first comparing the 2-sided 90% CI for RD of ACR20 at week 22 between ABP 710 and infliximab with an equivalence margin of (-15%, 15%). If the first test was successful, RD of ACR20 at week 22 was to be further evaluated by comparing the 2-sided 90% CI between ABP 710 and infliximab with an equivalence

| | |
|--|---------------------------------------|
| Statistical analysis title | Post-hoc Analysis of ACR20 at Week 22 |
| Statistical analysis description: | |
| A post-hoc analysis was conducted to adjust for the impact of random imbalance in baseline demographic and disease characteristics between the 2 treatment groups. The MH estimate of RD and corresponding CIs were estimated using a nonparametric analysis of covariance method with stratification factors geographic region and prior biologic use, and adjustment for baseline covariates (ACR core set, age, use of oral corticosteroid, use of NSAID, body mass index categories, and methotrexate dose). | |
| Comparison groups | ABP 710 v Infliximab |
| Number of subjects included in analysis | 558 |
| Analysis specification | Pre-specified |
| Analysis type | equivalence ^[3] |
| Parameter estimate | Response Difference |
| Point estimate | 7.184 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 0.748 |
| upper limit | 13.62 |

Notes:

[3] - Clinical equivalence for the primary endpoint was to be evaluated sequentially by first comparing the 2-sided 90% CI for RD of ACR20 at week 22 between ABP 710 and infliximab with an equivalence margin of (-15%, 15%). If the first test was successful, RD of ACR20 at week 22 was to be further evaluated by comparing the 2-sided 90% CI between ABP 710 and infliximab with an equivalence margin of (-12%, 15%).

Secondary: Percentage of Participants With an ACR20 Response Through Week 14

| | |
|--|---|
| End point title | Percentage of Participants With an ACR20 Response Through Week 14 |
| End point description: | |
| A positive ACR20 response is defined if the following 3 criteria for improvement from baseline were met: | |
| <ul style="list-style-type: none"> • ≥ 20% improvement in 68 tender joint count; • ≥ 20% improvement in 66 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: <ul style="list-style-type: none"> ◦ Patient's assessment of disease-related pain (measured on a 100 mm visual analog scale [VAS]); ◦ Patient's global health assessment (measured on a 100 mm VAS); ◦ Investigator's global health assessment (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]); ◦ C-reactive protein concentration. | |
| The analysis was conducted using the intent-to-treat population; participants with missing data at a given time point were counted as non-responders. | |
| End point type | Secondary |
| End point timeframe: | |
| Baseline and weeks 2, 6, and 14 | |

| End point values | ABP 710 | Infliximab | | |
|-----------------------------------|-----------------------|-----------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 279 | 279 | | |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | | | | |
| Week 2 | 46.2 (40.39 to 52.09) | 38.0 (32.30 to 43.69) | | |
| Week 6 | 64.9 (59.27 to 70.48) | 59.9 (54.10 to 65.61) | | |
| Week 14 | 66.3 (60.76 to 71.85) | 60.2 (54.47 to 65.96) | | |

Statistical analyses

| Statistical analysis title | Response Difference at Week 2 |
|--|-------------------------------|
| Statistical analysis description: | |
| The response difference at week 2 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use). | |
| Comparison groups | ABP 710 v Infliximab |
| Number of subjects included in analysis | 558 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | 8.03 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 1.15 |
| upper limit | 14.81 |

| Statistical analysis title | Response Difference at Week 14 |
|---|--------------------------------|
| Statistical analysis description: | |
| The response difference at week 14 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use). | |
| Comparison groups | ABP 710 v Infliximab |
| Number of subjects included in analysis | 558 |
| Analysis specification | Pre-specified |
| Analysis type | |
| Parameter estimate | Response Difference |
| Point estimate | 9.37 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -0.51 |
| upper limit | 12.87 |

| | |
|--|-------------------------------|
| Statistical analysis title | Response Difference at Week 6 |
| Statistical analysis description: | |
| The response difference at week 6 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use). | |
| Comparison groups | ABP 710 v Infliximab |
| Number of subjects included in analysis | 558 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | 4.96 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -1.8 |
| upper limit | 11.64 |

Secondary: Percentage of Participants With an ACR20 Response After Week 22

| | |
|-----------------|---|
| End point title | Percentage of Participants With an ACR20 Response After Week 22 |
|-----------------|---|

End point description:

A positive ACR20 response is defined if the following 3 criteria for improvement from baseline were met:

- $\geq 20\%$ improvement in 68 tender joint count;
- $\geq 20\%$ improvement in 66 swollen joint count; and
- $\geq 20\%$ improvement in at least 3 of the 5 following parameters:
 - Patient's assessment of disease-related pain (measured on a 100 mm visual analog scale [VAS]);
 - Patient's global health assessment (measured on a 100 mm VAS);
 - Investigator's global health assessment (measured on a 100 mm VAS);
 - Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
 - C-reactive protein concentration.

The analysis was conducted in participants re-randomized at week 22 (includes participants initially randomized to ABP 710 who continued treatment with ABP 710 at week 22); participants with missing data at a given visit were counted as non-responders.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and weeks 30, 34, 38, 46, and 50

| End point values | ABP 710 / ABP 710 | Infliximab / Infliximab | Infliximab / ABP 710 | |
|-----------------------------------|-----------------------|-------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 244 | 121 | 119 | |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | | | | |
| Week 30 | 69.7 (63.90 to 75.44) | 66.9 (58.56 to 75.32) | 74.8 (66.99 to 82.59) | |
| Week 34 | 74.6 (69.13 to 80.05) | 71.1 (63.00 to 79.15) | 74.8 (66.99 to 82.59) | |

| | | | | |
|---------|-----------------------|-----------------------|-----------------------|--|
| Week 38 | 70.5 (64.77 to 76.21) | 69.4 (61.21 to 77.63) | 72.3 (64.23 to 80.31) | |
| Week 46 | 61.9 (55.79 to 67.98) | 65.3 (56.81 to 73.77) | 66.4 (57.90 to 74.87) | |
| Week 50 | 67.6 (61.75 to 73.49) | 72.7 (64.79 to 80.66) | 70.6 (62.40 to 78.77) | |

Statistical analyses

| Statistical analysis title | Response Difference at Week 30 |
|---|---|
| Statistical analysis description: | |
| The response difference (ABP 710/ABP 710 minus Infliximab/Infliximab) at week 30 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use). | |
| Comparison groups | ABP 710 / ABP 710 v Infliximab / Infliximab |
| Number of subjects included in analysis | 365 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | 3.05 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -5.26 |
| upper limit | 11.73 |

| Statistical analysis title | Response Difference at Week 30 |
|--|--|
| Statistical analysis description: | |
| The response difference (Infliximab/ABP 710 minus Infliximab/Infliximab) at week 30 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use). | |
| Comparison groups | Infliximab / Infliximab v Infliximab / ABP 710 |
| Number of subjects included in analysis | 240 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | 8.5 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -1.18 |
| upper limit | 17.97 |

| Statistical analysis title | Response Difference at Week 34 |
|---|--------------------------------|
| Statistical analysis description: | |
| The response difference (ABP 710/ABP 710 minus Infliximab/Infliximab) at week 34 was estimated by | |

the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use).

| | |
|---|---|
| Comparison groups | ABP 710 / ABP 710 v Infliximab / Infliximab |
| Number of subjects included in analysis | 365 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | 3.31 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -4.61 |
| upper limit | 11.7 |

| | |
|--|--|
| Statistical analysis title | Response Difference at Week 34 |
| Statistical analysis description: | |
| The response difference (Infliximab/ABP 710 minus Infliximab/Infliximab) at week 34 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use). | |
| Comparison groups | Infliximab / Infliximab v Infliximab / ABP 710 |
| Number of subjects included in analysis | 240 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | 4.06 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -5.4 |
| upper limit | 13.4 |

| | |
|---|---|
| Statistical analysis title | Response Difference at Week 38 |
| Statistical analysis description: | |
| The response difference (ABP 710/ABP 710 minus Infliximab/Infliximab) at week 38 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use). | |
| Comparison groups | ABP 710 / ABP 710 v Infliximab / Infliximab |
| Number of subjects included in analysis | 365 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | 0.82 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -7.34 |
| upper limit | 9.4 |

| | |
|--|--|
| Statistical analysis title | Response Difference at Week 38 |
| Statistical analysis description: | |
| The response difference (Infliximab/ABP 710 minus Infliximab/Infliximab) at week 38 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use). | |
| Comparison groups | Infliximab / Infliximab v Infliximab / ABP 710 |
| Number of subjects included in analysis | 240 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | 2.79 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -6.86 |
| upper limit | 12.34 |

| | |
|---|---|
| Statistical analysis title | Response Difference at Week 46 |
| Statistical analysis description: | |
| The response difference (ABP 710/ABP 710 minus Infliximab/Infliximab) at week 46 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use). | |
| Comparison groups | ABP 710 / ABP 710 v Infliximab / Infliximab |
| Number of subjects included in analysis | 365 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | -3.74 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -12.27 |
| upper limit | 5.17 |

| | |
|--|--|
| Statistical analysis title | Response Difference at Week 46 |
| Statistical analysis description: | |
| The response difference (Infliximab/ABP 710 minus Infliximab/Infliximab) at week 46 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use). | |
| Comparison groups | Infliximab / Infliximab v Infliximab / ABP 710 |

| | |
|---|---------------------|
| Number of subjects included in analysis | 240 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | 1.12 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -8.89 |
| upper limit | 11.08 |

| | |
|-----------------------------------|--------------------------------|
| Statistical analysis title | Response Difference at Week 50 |
|-----------------------------------|--------------------------------|

Statistical analysis description:

The response difference (ABP 710/ABP 710 minus Infliximab/Infliximab) at week 50 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use).

| | |
|---|---|
| Comparison groups | ABP 710 / ABP 710 v Infliximab / Infliximab |
| Number of subjects included in analysis | 365 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| Parameter estimate | Response Difference |
| Point estimate | -5.25 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -13.24 |
| upper limit | 3.29 |

| | |
|-----------------------------------|--------------------------------|
| Statistical analysis title | Response Difference at Week 50 |
|-----------------------------------|--------------------------------|

Statistical analysis description:

The response difference (Infliximab/ABP 710 minus Infliximab/Infliximab) at week 50 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use).

| | |
|---|--|
| Comparison groups | Infliximab / Infliximab v Infliximab / ABP 710 |
| Number of subjects included in analysis | 240 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | -1.49 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -11.01 |
| upper limit | 8.04 |

Secondary: Percentage of Participants With an ACR50 Response Through Week 22

| | |
|-----------------|---|
| End point title | Percentage of Participants With an ACR50 Response Through Week 22 |
|-----------------|---|

End point description:

A positive ACR50 response is defined if the following 3 criteria for improvement from baseline were met:

- $\geq 50\%$ improvement in 68 tender joint count;
- $\geq 50\%$ improvement in 66 swollen joint count; and
- $\geq 50\%$ improvement in at least 3 of the 5 following parameters:
 - Patient's assessment of disease-related pain (measured on a 100 mm visual analog scale [VAS]);
 - Patient's global health assessment (measured on a 100 mm VAS);
 - Investigator's global health assessment (measured on a 100 mm VAS);
 - Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
 - C-reactive protein concentration.

The analysis was conducted in the intent-to-treat population; participants with missing data at a given time point were counted as non-responders.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and weeks 2, 6, 14, and 22

| End point values | ABP 710 | Infliximab | | |
|-----------------------------------|-----------------------|-----------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 279 | 279 | | |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | | | | |
| Week 2 | 17.2 (12.78 to 21.63) | 12.5 (8.66 to 16.43) | | |
| Week 6 | 30.1 (24.72 to 35.49) | 28.3 (23.03 to 33.60) | | |
| Week 14 | 39.4 (33.69 to 45.16) | 36.9 (31.25 to 42.58) | | |
| Week 22 | 43.0 (37.20 to 48.82) | 36.2 (30.56 to 41.84) | | |

Statistical analyses

| | |
|----------------------------|-------------------------------|
| Statistical analysis title | Response Difference at Week 2 |
|----------------------------|-------------------------------|

Statistical analysis description:

The response difference at week 2 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use).

| | |
|---|----------------------|
| Comparison groups | ABP 710 v Infliximab |
| Number of subjects included in analysis | 558 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | 4.41 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -0.56 |
| upper limit | 9.38 |

| | |
|-----------------------------------|-------------------------------|
| Statistical analysis title | Response Difference at Week 6 |
|-----------------------------------|-------------------------------|

Statistical analysis description:

The response difference at week 6 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use).

| | |
|---|----------------------|
| Comparison groups | ABP 710 v Infliximab |
| Number of subjects included in analysis | 558 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | 1.62 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -4.71 |
| upper limit | 7.94 |

| | |
|-----------------------------------|--------------------------------|
| Statistical analysis title | Response Difference at Week 14 |
|-----------------------------------|--------------------------------|

Statistical analysis description:

The response difference at week 14 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use).

| | |
|---|----------------------|
| Comparison groups | ABP 710 v Infliximab |
| Number of subjects included in analysis | 558 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | 2.3 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -4.45 |
| upper limit | 9.03 |

| | |
|-----------------------------------|--------------------------------|
| Statistical analysis title | Response Difference at Week 22 |
|-----------------------------------|--------------------------------|

Statistical analysis description:

The response difference at week 22 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use).

| | |
|---|----------------------|
| Comparison groups | ABP 710 v Infliximab |
| Number of subjects included in analysis | 558 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | 7.09 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 0.27 |
| upper limit | 13.83 |

Secondary: Percentage of Participants With an ACR50 Response After Week 22

| | |
|-----------------|---|
| End point title | Percentage of Participants With an ACR50 Response After Week 22 |
|-----------------|---|

End point description:

A positive ACR50 response is defined if the following 3 criteria for improvement from baseline were met:

- $\geq 50\%$ improvement in 68 tender joint count;
- $\geq 50\%$ improvement in 66 swollen joint count; and
- $\geq 50\%$ improvement in at least 3 of the 5 following parameters:
 - Patient's assessment of disease-related pain (measured on a 100 mm visual analog scale [VAS]);
 - Patient's global health assessment (measured on a 100 mm VAS);
 - Investigator's global health assessment (measured on a 100 mm VAS);
 - Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
 - C-reactive protein concentration.

The analysis was conducted in participants re-randomized at week 22 (includes participants initially randomized to ABP 710 who continued treatment with ABP 710 at week 22); participants with missing data at a given visit were counted as non-responders.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and weeks 30, 34, 38, 46, and 50

| End point values | ABP 710 / ABP 710 | Infliximab / Infliximab | Infliximab / ABP 710 | |
|-----------------------------------|-----------------------|-------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 244 | 121 | 119 | |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | | | | |
| Week 30 | 43.0 (36.82 to 49.25) | 44.6 (35.77 to 53.49) | 47.1 (38.09 to 56.03) | |
| Week 34 | 52.5 (46.19 to 58.73) | 46.3 (37.40 to 55.17) | 56.3 (47.39 to 65.21) | |
| Week 38 | 48.0 (41.68 to 54.22) | 47.1 (38.21 to 56.00) | 49.6 (40.60 to 58.56) | |
| Week 46 | 43.9 (37.63 to 50.08) | 44.6 (35.77 to 53.49) | 50.4 (41.44 to 59.40) | |
| Week 50 | 49.2 (42.91 to 55.45) | 54.5 (45.67 to 63.42) | 57.1 (48.25 to 66.03) | |

Statistical analyses

| | |
|--|---|
| Statistical analysis title | Response Difference at Week 30 |
| Statistical analysis description: The response difference (ABP 710/ABP 710 minus Infliximab/Infliximab) at week 30 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use). | |
| Comparison groups | ABP 710 / ABP 710 v Infliximab / Infliximab |
| Number of subjects included in analysis | 365 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | -1.33 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -10.4 |
| upper limit | 7.62 |

| | |
|---|--|
| Statistical analysis title | Response Difference at Week 30 |
| Statistical analysis description: The response difference (Infliximab/ABP 710 minus Infliximab/Infliximab) at week 30 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use). | |
| Comparison groups | Infliximab / Infliximab v Infliximab / ABP 710 |
| Number of subjects included in analysis | 240 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | 3.24 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -7.28 |
| upper limit | 13.67 |

| | |
|--|---|
| Statistical analysis title | Response Difference at Week 34 |
| Statistical analysis description: The response difference (ABP 710/ABP 710 minus Infliximab/Infliximab) at week 34 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use). | |
| Comparison groups | ABP 710 / ABP 710 v Infliximab / Infliximab |

| | |
|---|---------------------|
| Number of subjects included in analysis | 365 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | 6.52 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -2.62 |
| upper limit | 15.48 |

| | |
|-----------------------------------|--------------------------------|
| Statistical analysis title | Response Difference at Week 34 |
|-----------------------------------|--------------------------------|

Statistical analysis description:

The response difference (Infliximab/ABP 710 minus Infliximab/Infliximab) at week 34 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use).

| | |
|---|--|
| Comparison groups | Infliximab / Infliximab v Infliximab / ABP 710 |
| Number of subjects included in analysis | 240 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | 10.74 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 0.12 |
| upper limit | 21.03 |

| | |
|-----------------------------------|--------------------------------|
| Statistical analysis title | Response Difference at Week 38 |
|-----------------------------------|--------------------------------|

Statistical analysis description:

The response difference (ABP 710/ABP 710 minus Infliximab/Infliximab) at week 38 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use).

| | |
|---|---|
| Comparison groups | ABP 710 / ABP 710 v Infliximab / Infliximab |
| Number of subjects included in analysis | 365 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | 0.56 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -8.54 |
| upper limit | 9.59 |

| | |
|--|--|
| Statistical analysis title | Response Difference at Week 38 |
| Statistical analysis description: | |
| The response difference (Infliximab/ABP 710 minus Infliximab/Infliximab) at week 38 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use). | |
| Comparison groups | Infliximab / Infliximab v Infliximab / ABP 710 |
| Number of subjects included in analysis | 240 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | 2.93 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -7.62 |
| upper limit | 13.39 |

| | |
|---|---|
| Statistical analysis title | Response Difference at Week 46 |
| Statistical analysis description: | |
| The response difference (ABP 710/ABP 710 minus Infliximab/Infliximab) at week 46 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use). | |
| Comparison groups | ABP 710 / ABP 710 v Infliximab / Infliximab |
| Number of subjects included in analysis | 365 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | -1.04 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -10.11 |
| upper limit | 7.93 |

| | |
|--|--|
| Statistical analysis title | Response Difference at Week 46 |
| Statistical analysis description: | |
| The response difference (Infliximab/ABP 710 minus Infliximab/Infliximab) at week 46 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use). | |
| Comparison groups | Infliximab / Infliximab v Infliximab / ABP 710 |
| Number of subjects included in analysis | 240 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | 6.14 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -4.44 |
| upper limit | 16.54 |

| | |
|-----------------------------------|--------------------------------|
| Statistical analysis title | Response Difference at Week 50 |
|-----------------------------------|--------------------------------|

Statistical analysis description:

The response difference (ABP 710/ABP 710 minus Infliximab/Infliximab) at week 50 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use).

| | |
|---|---|
| Comparison groups | ABP 710 / ABP 710 v Infliximab / Infliximab |
| Number of subjects included in analysis | 365 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | -5.43 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -14.39 |
| upper limit | 3.71 |

| | |
|-----------------------------------|--------------------------------|
| Statistical analysis title | Response Difference at Week 50 |
|-----------------------------------|--------------------------------|

Statistical analysis description:

The response difference (Infliximab/ABP 710 minus Infliximab/Infliximab) at week 50 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use).

| | |
|---|--|
| Comparison groups | Infliximab / Infliximab v Infliximab / ABP 710 |
| Number of subjects included in analysis | 240 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | 2.98 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -7.51 |
| upper limit | 13.37 |

Secondary: Percentage of Participants With an ACR70 Response Through Week 22

| | |
|-----------------|---|
| End point title | Percentage of Participants With an ACR70 Response Through Week 22 |
|-----------------|---|

End point description:

A positive ACR70 response is defined if the following 3 criteria for improvement from baseline were met:

- $\geq 70\%$ improvement in 68 tender joint count;
- $\geq 70\%$ improvement in 66 swollen joint count; and
- $\geq 70\%$ improvement in at least 3 of the 5 following parameters:
 - Patient's assessment of disease-related pain (measured on a 100 mm visual analog scale [VAS]);
 - Patient's global health assessment (measured on a 100 mm VAS);
 - Investigator's global health assessment (measured on a 100 mm VAS);
 - Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
 - C-reactive protein concentration.

The analysis was conducted in the intent-to-treat population; participants with missing data at a given visit were counted as non-responders.

| | |
|-------------------------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Baseline and weeks 2, 6, 14, and 22 | |

| End point values | ABP 710 | Infliximab | | |
|-----------------------------------|-----------------------|-----------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 279 | 279 | | |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | | | | |
| Week 2 | 3.9 (1.66 to 6.23) | 6.5 (3.57 to 9.33) | | |
| Week 6 | 14.3 (10.22 to 18.45) | 16.5 (12.13 to 20.84) | | |
| Week 14 | 21.9 (17.01 to 26.71) | 16.1 (11.81 to 20.44) | | |
| Week 22 | 24.0 (19.00 to 29.03) | 19.7 (15.05 to 24.38) | | |

Statistical analyses

| | |
|--|-------------------------------|
| Statistical analysis title | Response Difference at Week 2 |
| Statistical analysis description: | |
| The response difference at week 2 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use). | |
| Comparison groups | ABP 710 v Infliximab |
| Number of subjects included in analysis | 558 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | -2.5 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -5.84 |
| upper limit | 0.83 |

| | |
|--|-------------------------------|
| Statistical analysis title | Response Difference at Week 6 |
| Statistical analysis description: | |
| The response difference at week 6 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use). | |
| Comparison groups | ABP 710 v Infliximab |
| Number of subjects included in analysis | 558 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | -2.43 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -7.47 |
| upper limit | 2.64 |

| | |
|---|--------------------------------|
| Statistical analysis title | Response Difference at Week 14 |
| Statistical analysis description: | |
| The response difference at week 14 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use). | |
| Comparison groups | ABP 710 v Infliximab |
| Number of subjects included in analysis | 558 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | 5.46 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -0.01 |
| upper limit | 10.91 |

| | |
|---|--------------------------------|
| Statistical analysis title | Response Difference at Week 22 |
| Statistical analysis description: | |
| The response difference at week 22 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use). | |
| Comparison groups | ABP 710 v Infliximab |
| Number of subjects included in analysis | 558 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | 4.58 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -1.21 |
| upper limit | 10.34 |

Secondary: Percentage of Participants With an ACR70 Response After Week 22

| | |
|-----------------|---|
| End point title | Percentage of Participants With an ACR70 Response After Week 22 |
|-----------------|---|

End point description:

A positive ACR70 response is defined if the following 3 criteria for improvement from baseline were met:

- $\geq 70\%$ improvement in 68 tender joint count;
- $\geq 70\%$ improvement in 66 swollen joint count; and
- $\geq 70\%$ improvement in at least 3 of the 5 following parameters:
 - Patient's assessment of disease-related pain (measured on a 100 mm visual analog scale [VAS]);
 - Patient's global health assessment (measured on a 100 mm VAS);
 - Investigator's global health assessment (measured on a 100 mm VAS);
 - Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
 - C-reactive protein concentration.

The analysis was conducted in participants re-randomized at week 22 (includes participants initially randomized to ABP 710 who continued treatment with ABP 710 at week 22); participants with missing data at a given visit were counted as non-responders.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and weeks 30, 34, 38, 46, and 50

| End point values | ABP 710 / ABP 710 | Infliximab / Infliximab | Infliximab / ABP 710 | |
|-----------------------------------|-----------------------|-------------------------|-----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 244 | 121 | 119 | |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | | | | |
| Week 30 | 26.6 (21.09 to 32.19) | 26.4 (18.59 to 34.30) | 26.1 (18.16 to 33.94) | |
| Week 34 | 29.5 (23.79 to 35.23) | 28.1 (20.09 to 36.11) | 35.3 (26.71 to 43.88) | |
| Week 38 | 29.1 (23.40 to 34.80) | 29.8 (21.61 to 37.90) | 32.8 (24.34 to 41.21) | |
| Week 46 | 29.5 (23.79 to 35.23) | 29.8 (21.61 to 37.90) | 37.0 (28.30 to 45.65) | |
| Week 50 | 34.0 (28.07 to 39.96) | 32.2 (23.90 to 40.56) | 43.7 (34.79 to 52.61) | |

Statistical analyses

| | |
|----------------------------|--------------------------------|
| Statistical analysis title | Response Difference at Week 30 |
|----------------------------|--------------------------------|

Statistical analysis description:

The response difference (ABP 710/ABP 710 minus Infliximab/Infliximab) at week 30 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe

confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use).

| | |
|---|---|
| Comparison groups | ABP 710 / ABP 710 v Infliximab / Infliximab |
| Number of subjects included in analysis | 365 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | 0.2 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -8.12 |
| upper limit | 8.02 |

Statistical analysis title

Response Difference at Week 30

Statistical analysis description:

The response difference (Infliximab/ABP 710 minus Infliximab/Infliximab) at week 30 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use).

| | |
|---|--|
| Comparison groups | Infliximab / Infliximab v Infliximab / ABP 710 |
| Number of subjects included in analysis | 240 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | -0.08 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -9.39 |
| upper limit | 9.28 |

Statistical analysis title

Response Difference at Week 34

Statistical analysis description:

The response difference (ABP 710/ABP 710 minus Infliximab/Infliximab) at week 34 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use).

| | |
|---|---|
| Comparison groups | ABP 710 / ABP 710 v Infliximab / Infliximab |
| Number of subjects included in analysis | 365 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | 1.5 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -7 |
| upper limit | 9.51 |

| | |
|--|--|
| Statistical analysis title | Response Difference at Week 34 |
| Statistical analysis description: | |
| The response difference (Infliximab/ABP 710 minus Infliximab/Infliximab) at week 34 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use). | |
| Comparison groups | Infliximab / Infliximab v Infliximab / ABP 710 |
| Number of subjects included in analysis | 240 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | 7.49 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -2.39 |
| upper limit | 17.22 |

| | |
|---|---|
| Statistical analysis title | Response Difference at Week 38 |
| Statistical analysis description: | |
| The response difference (ABP 710/ABP 710 minus Infliximab/Infliximab) at week 38 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use). | |
| Comparison groups | ABP 710 / ABP 710 v Infliximab / Infliximab |
| Number of subjects included in analysis | 365 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | -0.5 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -9.03 |
| upper limit | 7.59 |

| | |
|--|--|
| Statistical analysis title | Response Difference at Week 38 |
| Statistical analysis description: | |
| The response difference (Infliximab/ABP 710 minus Infliximab/Infliximab) at week 38 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use). | |
| Comparison groups | Infliximab / Infliximab v Infliximab / ABP 710 |

| | |
|---|---------------------|
| Number of subjects included in analysis | 240 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | 3.39 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -6.41 |
| upper limit | 13.14 |

| | |
|-----------------------------------|--------------------------------|
| Statistical analysis title | Response Difference at Week 46 |
|-----------------------------------|--------------------------------|

Statistical analysis description:

The response difference (ABP 710/ABP 710 minus Infliximab/Infliximab) at week 46 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use).

| | |
|---|---|
| Comparison groups | ABP 710 / ABP 710 v Infliximab / Infliximab |
| Number of subjects included in analysis | 365 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | -0.43 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -8.98 |
| upper limit | 7.66 |

| | |
|-----------------------------------|--------------------------------|
| Statistical analysis title | Response Difference at Week 46 |
|-----------------------------------|--------------------------------|

Statistical analysis description:

The response difference (Infliximab/ABP 710 minus Infliximab/Infliximab) at week 46 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use).

| | |
|---|--|
| Comparison groups | Infliximab / Infliximab v Infliximab / ABP 710 |
| Number of subjects included in analysis | 240 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | 7.87 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -2.13 |
| upper limit | 17.68 |

| | |
|---|---|
| Statistical analysis title | Response Difference at Week 50 |
| Statistical analysis description: | |
| The response difference (ABP 710/ABP 710 minus Infliximab/Infliximab) at week 50 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use). | |
| Comparison groups | ABP 710 / ABP 710 v Infliximab / Infliximab |
| Number of subjects included in analysis | 365 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | 1.95 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -6.81 |
| upper limit | 10.29 |

| | |
|--|--|
| Statistical analysis title | Response Difference at Week 50 |
| Statistical analysis description: | |
| The response difference (Infliximab/ABP 710 minus Infliximab/Infliximab) at week 50 was estimated by the Mantel-Haenszel estimate; 90% confidence intervals were estimated from the stratified Newcombe confidence limits, adjusting for actual stratification factors (geographic region and prior biologic use). | |
| Comparison groups | Infliximab / Infliximab v Infliximab / ABP 710 |
| Number of subjects included in analysis | 240 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Response Difference |
| Point estimate | 12.06 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 1.74 |
| upper limit | 22.04 |

Secondary: Change from Baseline in Disease Activity Score 28 (DAS28) Through Week 22

| | |
|-----------------|---|
| End point title | Change from Baseline in Disease Activity Score 28 (DAS28) Through Week 22 |
|-----------------|---|

End point description:

The DAS28 measures the severity of disease at a specific time and is derived from the following variables:

- 28 tender joint count
- 28 swollen joint count
- C-reactive protein (CRP)
- Patient's global health assessment measured on a 100 mm VAS, where 0 mm = no RA activity and 100 mm = worst RA activity imaginable.

DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission. The analysis was conducted in the intent-to-treat population with available data at each time point.

| | |
|-------------------------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Baseline and weeks 2, 6, 14, and 22 | |

| End point values | ABP 710 | Infliximab | | |
|--------------------------------------|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 279 | 279 | | |
| Units: units on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Week 2 (N = 260, 255) | -1.36 (± 0.991) | -1.29 (± 1.006) | | |
| Week 6 (N = 259,253) | -1.82 (± 1.222) | -1.82 (± 1.203) | | |
| Week 14 (N = 253, 250) | -1.95 (± 1.218) | -1.91 (± 1.289) | | |
| Week 22 (N = 245, 243) | -2.06 (± 1.290) | -2.06 (± 1.296) | | |

Statistical analyses

| Statistical analysis title | Mean Difference at Week 2 |
|--|---------------------------|
| Statistical analysis description: | |
| Week 2 difference between means (ABP 710 minus infliximab) and 90% CIs for difference between means were based on ANCOVA model with the DAS28-CRP change from baseline as the response and adjusted for the baseline DAS28-CRP measurement and the actual stratification factors: geographic region and prior biologic use for RA. | |
| Comparison groups | ABP 710 v Infliximab |
| Number of subjects included in analysis | 558 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Mean Difference |
| Point estimate | -0.07 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -0.2 |
| upper limit | 0.007 |

| Statistical analysis title | Mean Difference at Week 6 |
|--|---------------------------|
| Statistical analysis description: | |
| Week 6 difference between means (ABP 710 minus infliximab) and 90% CIs for difference between means were based on ANCOVA model with the DAS28-CRP change from baseline as the response and adjusted for the baseline DAS28-CRP measurement and the actual stratification factors: geographic region and prior biologic use for RA. | |
| Comparison groups | ABP 710 v Infliximab |

| | |
|---|-----------------|
| Number of subjects included in analysis | 558 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Mean Difference |
| Point estimate | 0 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -0.17 |
| upper limit | 0.16 |

| | |
|-----------------------------------|----------------------------|
| Statistical analysis title | Mean Difference at Week 14 |
|-----------------------------------|----------------------------|

Statistical analysis description:

Week 14 difference between means (ABP 710 minus infliximab) and 90% CIs for difference between means were based on ANCOVA model with the DAS28-CRP change from baseline as the response and adjusted for the baseline DAS28-CRP measurement and the actual stratification factors: geographic region and prior biologic use for RA.

| | |
|---|----------------------|
| Comparison groups | ABP 710 v Infliximab |
| Number of subjects included in analysis | 558 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Mean Difference |
| Point estimate | -0.04 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -0.21 |
| upper limit | 0.14 |

| | |
|-----------------------------------|----------------------------|
| Statistical analysis title | Mean Difference at Week 22 |
|-----------------------------------|----------------------------|

Statistical analysis description:

Week 22 difference between means (ABP 710 minus infliximab) and 90% CIs for difference between means were based on ANCOVA model with the DAS28-CRP change from baseline as the response and adjusted for the baseline DAS28-CRP measurement and the actual stratification factors: geographic region and prior biologic use for RA.

| | |
|---|----------------------|
| Comparison groups | ABP 710 v Infliximab |
| Number of subjects included in analysis | 558 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Mean Difference |
| Point estimate | -0.01 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -0.2 |
| upper limit | 0.17 |

Secondary: Change from Baseline in Disease Activity Score 28 (DAS28) After Week 22

| | |
|-----------------|---|
| End point title | Change from Baseline in Disease Activity Score 28 (DAS28) After Week 22 |
|-----------------|---|

End point description:

The DAS28 measures the severity of disease at a specific time and is derived from the following variables:

- 28 tender joint count
- 28 swollen joint count
- C-reactive protein (CRP)
- Patient's global health assessment measured on a 100 mm VAS, where 0 mm = no RA activity and 100 mm = worst RA activity imaginable.

DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission. The analysis was conducted in participants re-randomized at week 22 (includes participants initially randomized to ABP 710 who continued treatment with ABP 710 at week 22) with available data.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and weeks 30, 34, 38, 46, and 50

| End point values | ABP 710 / ABP 710 | Infliximab / Infliximab | Infliximab / ABP 710 | |
|--------------------------------------|-------------------|-------------------------|----------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 244 | 121 | 119 | |
| Units: units on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Week 30 (N = 225, 112, 112) | -2.07 (± 1.278) | -2.25 (± 1.379) | -2.22 (± 1.266) | |
| Week 34 (N = 222, 113, 111) | -2.32 (± 1.306) | -2.46 (± 1.372) | -2.45 (± 1.309) | |
| Week 38 (N = 219, 114, 110) | -2.20 (± 1.277) | -2.27 (± 1.301) | -2.32 (± 1.400) | |
| Week 46 (N = 205, 108, 108) | -2.11 (± 1.381) | -2.27 (± 1.387) | -2.26 (± 1.440) | |
| Week 50 (N = 203, 110, 107) | -2.45 (± 1.365) | -2.49 (± 1.276) | -2.64 (± 1.328) | |

Statistical analyses

| | |
|----------------------------|----------------------------|
| Statistical analysis title | Mean Difference at Week 30 |
|----------------------------|----------------------------|

Statistical analysis description:

Week 30 difference between means (ABP 710/ABP 710 minus Infliximab/Infliximab) and 90% CIs for difference between means were based on ANCOVA model with the DAS28-CRP change from baseline as the response and adjusted for the baseline DAS28-CRP measurement and the actual stratification factors: geographic region and prior biologic use for RA.

| | |
|-------------------|---|
| Comparison groups | ABP 710 / ABP 710 v Infliximab / Infliximab |
|-------------------|---|

| | |
|---|-----------------|
| Number of subjects included in analysis | 365 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Mean Difference |
| Point estimate | 0.16 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -0.08 |
| upper limit | 0.4 |

| | |
|-----------------------------------|----------------------------|
| Statistical analysis title | Mean Difference at Week 30 |
|-----------------------------------|----------------------------|

Statistical analysis description:

Week 30 difference between means (Infliximab/ABP 710 minus Infliximab/Infliximab) and 90% CIs for difference between means were based on ANCOVA model with the DAS28-CRP change from baseline as the response and adjusted for the baseline DAS28-CRP measurement and the actual stratification factors: geographic region and prior biologic use for RA.

| | |
|---|--|
| Comparison groups | Infliximab / Infliximab v Infliximab / ABP 710 |
| Number of subjects included in analysis | 240 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Mean Difference |
| Point estimate | 0 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -0.27 |
| upper limit | 0.28 |

| | |
|-----------------------------------|----------------------------|
| Statistical analysis title | Mean Difference at Week 34 |
|-----------------------------------|----------------------------|

Statistical analysis description:

Week 34 difference between means (ABP 710/ABP 710 minus Infliximab/Infliximab) and 90% CIs for difference between means were based on ANCOVA model with the DAS28-CRP change from baseline as the response and adjusted for the baseline DAS28-CRP measurement and the actual stratification factors: geographic region and prior biologic use for RA.

| | |
|---|---|
| Comparison groups | ABP 710 / ABP 710 v Infliximab / Infliximab |
| Number of subjects included in analysis | 365 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Mean Difference |
| Point estimate | 0.11 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -0.12 |
| upper limit | 0.35 |

| | |
|---|--|
| Statistical analysis title | Mean Difference at Week 34 |
| Statistical analysis description: | |
| Week 34 difference between means (Infliximab/ABP 710 minus Infliximab/Infliximab) and 90% CIs for difference between means were based on ANCOVA model with the DAS28-CRP change from baseline as the response and adjusted for the baseline DAS28-CRP measurement and the actual stratification factors: geographic region and prior biologic use for RA. | |
| Comparison groups | Infliximab / Infliximab v Infliximab / ABP 710 |
| Number of subjects included in analysis | 240 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Mean Difference |
| Point estimate | -0.03 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -0.3 |
| upper limit | 0.24 |

| | |
|--|---|
| Statistical analysis title | Mean Difference at Week 38 |
| Statistical analysis description: | |
| Week 38 difference between means (ABP 710/ABP 710 minus Infliximab/Infliximab) and 90% CIs for difference between means were based on ANCOVA model with the DAS28-CRP change from baseline as the response and adjusted for the baseline DAS28-CRP measurement and the actual stratification factors: geographic region and prior biologic use for RA. | |
| Comparison groups | ABP 710 / ABP 710 v Infliximab / Infliximab |
| Number of subjects included in analysis | 365 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Mean Difference |
| Point estimate | 0.06 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -0.18 |
| upper limit | 0.3 |

| | |
|---|--|
| Statistical analysis title | Mean Difference at Week 38 |
| Statistical analysis description: | |
| Week 38 difference between means (Infliximab/ABP 710 minus Infliximab/Infliximab) and 90% CIs for difference between means were based on ANCOVA model with the DAS28-CRP change from baseline as the response and adjusted for the baseline DAS28-CRP measurement and the actual stratification factors: geographic region and prior biologic use for RA. | |
| Comparison groups | Infliximab / Infliximab v Infliximab / ABP 710 |

| | |
|---|-----------------|
| Number of subjects included in analysis | 240 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Mean Difference |
| Point estimate | -0.08 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -0.36 |
| upper limit | 0.2 |

| | |
|-----------------------------------|----------------------------|
| Statistical analysis title | Mean Difference at Week 46 |
|-----------------------------------|----------------------------|

Statistical analysis description:

Week 46 difference between means (ABP 710/ABP 710 minus Infliximab/Infliximab) and 90% CIs for difference between means were based on ANCOVA model with the DAS28-CRP change from baseline as the response and adjusted for the baseline DAS28-CRP measurement and the actual stratification factors: geographic region and prior biologic use for RA.

| | |
|---|---|
| Comparison groups | ABP 710 / ABP 710 v Infliximab / Infliximab |
| Number of subjects included in analysis | 365 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Mean Difference |
| Point estimate | 0.11 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -0.14 |
| upper limit | 0.37 |

| | |
|-----------------------------------|----------------------------|
| Statistical analysis title | Mean Difference at Week 46 |
|-----------------------------------|----------------------------|

Statistical analysis description:

Week 46 difference between means (Infliximab/ABP 710 minus Infliximab/Infliximab) and 90% CIs for difference between means were based on ANCOVA model with the DAS28-CRP change from baseline as the response and adjusted for the baseline DAS28-CRP measurement and the actual stratification factors: geographic region and prior biologic use for RA.

| | |
|---|--|
| Comparison groups | Infliximab / Infliximab v Infliximab / ABP 710 |
| Number of subjects included in analysis | 240 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Mean Difference |
| Point estimate | -0.05 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -0.34 |
| upper limit | 0.25 |

| | |
|--|---|
| Statistical analysis title | Mean Difference at Week 50 |
| Statistical analysis description: | |
| Week 50 difference between means (ABP 710/ABP 710 minus Infliximab/Infliximab) and 90% CIs for difference between means were based on ANCOVA model with the DAS28-CRP change from baseline as the response and adjusted for the baseline DAS28-CRP measurement and the actual stratification factors: geographic region and prior biologic use for RA. | |
| Comparison groups | ABP 710 / ABP 710 v Infliximab / Infliximab |
| Number of subjects included in analysis | 365 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Mean Difference |
| Point estimate | 0 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -0.24 |
| upper limit | 0.24 |

| | |
|---|--|
| Statistical analysis title | Mean Difference at Week 50 |
| Statistical analysis description: | |
| Week 50 difference between means (Infliximab/ABP 710 minus Infliximab/Infliximab) and 90% CIs for difference between means were based on ANCOVA model with the DAS28-CRP change from baseline as the response and adjusted for the baseline DAS28-CRP measurement and the actual stratification factors: geographic region and prior biologic use for RA. | |
| Comparison groups | Infliximab / Infliximab v Infliximab / ABP 710 |
| Number of subjects included in analysis | 240 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Mean Difference |
| Point estimate | -0.2 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -0.47 |
| upper limit | 0.08 |

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From first dose to week 22 (initial ABP 710 and infliximab treatment groups) and from week 22 to week 50 for participants re-randomized at week 22, or up to 28 days after last dose for participants who discontinued early.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|--------------------|--------|
| Dictionary name | MedDRA |
| Dictionary version | 20.1 |

Reporting groups

| | |
|-----------------------|---------|
| Reporting group title | ABP 710 |
|-----------------------|---------|

Reporting group description:

Participants received 3 mg/kg intravenous (IV) infusion of ABP 710 on day 1, at weeks 2 and 6, and every 8 weeks thereafter until week 22.

| | |
|-----------------------|------------|
| Reporting group title | Infliximab |
|-----------------------|------------|

Reporting group description:

Participants received 3 mg/kg IV infusion of infliximab on day 1, at weeks 2 and 6, and every 8 weeks thereafter until week 22.

| | |
|-----------------------|-------------------|
| Reporting group title | ABP 710 / ABP 710 |
|-----------------------|-------------------|

Reporting group description:

At week 22 participants initially randomized to ABP 710 continued receiving 3 mg/kg ABP 710 every 8 weeks through week 46.

| | |
|-----------------------|-------------------------|
| Reporting group title | Infliximab / Infliximab |
|-----------------------|-------------------------|

Reporting group description:

At week 22 participants initially randomized to infliximab were re-randomized to continue receiving 3 mg/kg infliximab every 8 weeks through week 46.

| | |
|-----------------------|----------------------|
| Reporting group title | Infliximab / ABP 710 |
|-----------------------|----------------------|

Reporting group description:

At week 22 participants initially randomized to infliximab were re-randomized to receive 3 mg/kg ABP 710 every 8 weeks through week 46.

| Serious adverse events | ABP 710 | Infliximab | ABP 710 / ABP 710 |
|---|-----------------|------------------|-------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 9 / 278 (3.24%) | 14 / 278 (5.04%) | 15 / 241 (6.22%) |
| number of deaths (all causes) | 1 | 1 | 0 |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Chronic lymphocytic leukaemia | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 1 / 278 (0.36%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Endometrial adenocarcinoma | | | |

| | | | |
|--|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 278 (0.36%) | 0 / 278 (0.00%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Malignant melanoma | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 0 / 278 (0.00%) | 1 / 241 (0.41%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ovarian low malignant potential tumour | | | |
| subjects affected / exposed | 1 / 278 (0.36%) | 0 / 278 (0.00%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Transitional cell carcinoma | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 1 / 278 (0.36%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Orthostatic hypotension | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 1 / 278 (0.36%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral ischaemia | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 0 / 278 (0.00%) | 1 / 241 (0.41%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thrombosis | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 2 / 278 (0.72%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| Chest discomfort | | | |
| subjects affected / exposed | 1 / 278 (0.36%) | 0 / 278 (0.00%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|-----------------|-----------------|
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 0 / 278 (0.00%) | 1 / 241 (0.41%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Pulmonary embolism | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 0 / 278 (0.00%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Transaminases increased | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 0 / 278 (0.00%) | 1 / 241 (0.41%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| Femoral neck fracture | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 0 / 278 (0.00%) | 1 / 241 (0.41%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hip fracture | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 0 / 278 (0.00%) | 1 / 241 (0.41%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Laceration | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 0 / 278 (0.00%) | 1 / 241 (0.41%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Multiple injuries | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 1 / 278 (0.36%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Tibia fracture | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 278 (0.00%) | 1 / 278 (0.36%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Acute myocardial infarction | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 1 / 278 (0.36%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac failure congestive | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 0 / 278 (0.00%) | 1 / 241 (0.41%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiovascular insufficiency | | | |
| subjects affected / exposed | 1 / 278 (0.36%) | 0 / 278 (0.00%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myocardial infarction | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 1 / 278 (0.36%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ventricular extrasystoles | | | |
| subjects affected / exposed | 1 / 278 (0.36%) | 0 / 278 (0.00%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Sciatica | | | |
| subjects affected / exposed | 1 / 278 (0.36%) | 0 / 278 (0.00%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Transient ischaemic attack | | | |
| subjects affected / exposed | 1 / 278 (0.36%) | 0 / 278 (0.00%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 0 / 278 (0.00%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Microcytic anaemia | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 0 / 278 (0.00%) | 1 / 241 (0.41%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Colitis | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 1 / 278 (0.36%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Constipation | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 1 / 278 (0.36%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis acute | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 0 / 278 (0.00%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Jaundice cholestatic | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 0 / 278 (0.00%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Dermatitis atopic | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 0 / 278 (0.00%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Nephrolithiasis | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 278 (0.00%) | 1 / 278 (0.36%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal failure | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 1 / 278 (0.36%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ureterolithiasis | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 1 / 278 (0.36%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 0 / 278 (0.00%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Foot deformity | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 0 / 278 (0.00%) | 2 / 241 (0.83%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Muscular weakness | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 1 / 278 (0.36%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rheumatoid arthritis | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 0 / 278 (0.00%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Appendicitis | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 0 / 278 (0.00%) | 1 / 241 (0.41%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|-----------------|-----------------|
| Arthritis bacterial | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 1 / 278 (0.36%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 0 / 278 (0.00%) | 2 / 241 (0.83%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Febrile infection | | | |
| subjects affected / exposed | 1 / 278 (0.36%) | 0 / 278 (0.00%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 0 / 278 (0.00%) | 1 / 241 (0.41%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia bacterial | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 1 / 278 (0.36%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia legionella | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 1 / 278 (0.36%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia pneumococcal | | | |
| subjects affected / exposed | 1 / 278 (0.36%) | 0 / 278 (0.00%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 2 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| Pneumonia viral | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 1 / 278 (0.36%) | 0 / 241 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| Dehydration | | | |
| subjects affected / exposed | 0 / 278 (0.00%) | 0 / 278 (0.00%) | 1 / 241 (0.41%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | Infliximab / Infliximab | Infliximab / ABP 710 | |
|---|------------------------------------|-----------------------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 4 / 121 (3.31%) | 1 / 119 (0.84%) | |
| number of deaths (all causes) | 0 | 0 | |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Chronic lymphocytic leukaemia | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Endometrial adenocarcinoma | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Malignant melanoma | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ovarian low malignant potential tumour | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Transitional cell carcinoma | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular disorders | | | |
| Orthostatic hypotension | | | |

| | | | |
|--|-----------------|-----------------|--|
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peripheral ischaemia | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thrombosis | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General disorders and administration site conditions | | | |
| Chest discomfort | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Pulmonary embolism | | | |
| subjects affected / exposed | 1 / 121 (0.83%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Investigations | | | |
| Transaminases increased | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Injury, poisoning and procedural complications | | | |
| Femoral neck fracture | | | |

| | | | |
|---|-----------------|-----------------|--|
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hip fracture | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Laceration | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Multiple injuries | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tibia fracture | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac disorders | | | |
| Acute myocardial infarction | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac failure congestive | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiovascular insufficiency | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myocardial infarction | | | |

| | | | |
|---|-----------------|-----------------|--|
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ventricular extrasystoles | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nervous system disorders | | | |
| Sciatica | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Transient ischaemic attack | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood and lymphatic system disorders | | | |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 1 / 119 (0.84%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Microcytic anaemia | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal disorders | | | |
| Colitis | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Constipation | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|-----------------|-----------------|--|
| Pancreatitis acute | | | |
| subjects affected / exposed | 1 / 121 (0.83%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatobiliary disorders | | | |
| Jaundice cholestatic | | | |
| subjects affected / exposed | 1 / 121 (0.83%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Skin and subcutaneous tissue disorders | | | |
| Dermatitis atopic | | | |
| subjects affected / exposed | 1 / 121 (0.83%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal and urinary disorders | | | |
| Nephrolithiasis | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal failure | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ureterolithiasis | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 1 / 121 (0.83%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Foot deformity | | | |

| | | | |
|---|-----------------|-----------------|--|
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Muscular weakness | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rheumatoid arthritis | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 1 / 119 (0.84%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| Appendicitis | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arthritis bacterial | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Febrile infection | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia bacterial | | | |

| | | | |
|---|-----------------|-----------------|--|
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia legionella | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia pneumococcal | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia viral | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 0 / 121 (0.00%) | 0 / 119 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | ABP 710 | Infliximab | ABP 710 / ABP 710 |
|---|-------------------|-------------------|-------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 48 / 278 (17.27%) | 32 / 278 (11.51%) | 52 / 241 (21.58%) |
| Musculoskeletal and connective tissue disorders | | | |
| Rheumatoid arthritis | | | |
| subjects affected / exposed | 14 / 278 (5.04%) | 11 / 278 (3.96%) | 23 / 241 (9.54%) |
| occurrences (all) | 14 | 11 | 23 |
| Infections and infestations | | | |
| Nasopharyngitis | | | |
| subjects affected / exposed | 12 / 278 (4.32%) | 4 / 278 (1.44%) | 13 / 241 (5.39%) |
| occurrences (all) | 12 | 4 | 13 |
| Pharyngitis | | | |

| | | | |
|-----------------------------------|------------------|------------------|------------------|
| subjects affected / exposed | 8 / 278 (2.88%) | 3 / 278 (1.08%) | 2 / 241 (0.83%) |
| occurrences (all) | 8 | 3 | 2 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 17 / 278 (6.12%) | 18 / 278 (6.47%) | 23 / 241 (9.54%) |
| occurrences (all) | 18 | 18 | 26 |

| Non-serious adverse events | Infliximab / Infliximab | Infliximab / ABP 710 | |
|---|----------------------------|----------------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 28 / 121 (23.14%) | 30 / 119 (25.21%) | |
| Musculoskeletal and connective tissue disorders | | | |
| Rheumatoid arthritis | | | |
| subjects affected / exposed | 9 / 121 (7.44%) | 7 / 119 (5.88%) | |
| occurrences (all) | 10 | 9 | |
| Infections and infestations | | | |
| Nasopharyngitis | | | |
| subjects affected / exposed | 11 / 121 (9.09%) | 8 / 119 (6.72%) | |
| occurrences (all) | 12 | 10 | |
| Pharyngitis | | | |
| subjects affected / exposed | 2 / 121 (1.65%) | 7 / 119 (5.88%) | |
| occurrences (all) | 2 | 7 | |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 9 / 121 (7.44%) | 14 / 119 (11.76%) | |
| occurrences (all) | 9 | 16 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|---------------|--|
| 17 March 2017 | <ul style="list-style-type: none">- Clarified the premedication requirement.- Specified that subjects who were unable to complete the week 22 visit within the allowed window were to be discontinued from the study and that these subjects should return for an EOS visit to complete the EOS assessments within 28 days, if possible.- Specified that subjects who were unable to complete the screening procedures within 28 days before baseline would be considered screen failures. Specified that these subjects could be rescreened, and they may be rescreened under the same informed consent form if rescreening occurred within 30 days.- Removed "adverse events" from the list of examples of "Reasons for removal of a subject from the study."- Emphasized that preinfusion PK samples were required to be drawn within 1 hour before dosing and that end-of-infusion PK samples were required to be collected within 10 minutes of completing the infusion.- Specified that 95% CIs, in addition to 90% CIs, would be presented for efficacy endpoints.- Clarified the inclusion and exclusion criteria. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported